O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-5.92%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.16B
AUM Growth
+$4.16B
(-14%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-4.24%
Top 10 Holdings %
Top 10 Hldgs %
48.04%
Holding
122
New
11
Increased
15
Reduced
22
Closed
16
Top Buys
| 1 |
Pfizer
PFE
|
$97.6M |
| 2 |
Axsome Therapeutics
AXSM
|
$45.1M |
| 3 |
SION
Sionna Therapeutics, Inc. Common Stock
SION
|
$38.8M |
| 4 |
UnitedHealth
UNH
|
$36.8M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$33.6M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$117M |
| 2 |
Merck
MRK
|
$82.6M |
| 3 |
Biogen
BIIB
|
$77.9M |
| 4 |
Intuitive Surgical
ISRG
|
$54.8M |
| 5 |
Universal Health Services
UHS
|
$48.3M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
NextCure
NXTC
$13.3M
| $548K | 0.01% |
1,141,200
| – | – |
|
102
Alto Neuroscience
ANRO
$97.7M
| $540K | 0.01% |
250,000
| – | – |
|
103
DIH Holdings US
DHAI
$12.2M
| $443K | 0.01% |
+1,915,000
| New | +$443K |
|
104
Xeris Biopharma Holdings
XERS
$1.27B
| $442K | 0.01% |
80,420
| – | – |
|
|
LSB
105
LakeShore Biopharma
LSB
$34.9M
| $344K | 0.01% |
140,428
| – | – |
|
|
ARDT
106
Ardent Health, Inc.
ARDT
$1.83B
| – | – |
-206,000
| Closed | -$3.52M |
|
107
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
-372,000
| Closed | -$33.5M |
|
|
108
Universal Health Services
UHS
$11.6B
| – | – |
-269,300
| Closed | -$48.3M |
|
|
109
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
-963,400
| Closed | -$117M |
|
110
PepGen
PEPG
$39M
| – | – |
-653,016
| Closed | -$2.47M |
|
111
Neumora Therapeutics
NMRA
$283M
| – | – |
-804,996
| Closed | -$8.53M |
|
|
112
Merck
MRK
$210B
| – | – |
-829,900
| Closed | -$82.6M |
|
113
Milestone Pharmaceuticals
MIST
$151M
| – | – |
-2,000,000
| Closed | -$4.72M |
|
114
Medpace
MEDP
$13.5B
| – | – |
-44,900
| Closed | -$14.9M |
|
115
Lyell Immunopharma
LYEL
$220M
| – | – |
-3,103,623
| Closed | -$1.99M |
|
116
Immunovant
IMVT
$2.91B
| – | – |
-78,500
| Closed | -$1.94M |
|
117
Geron
GERN
$893M
| – | – |
-2,168,000
| Closed | -$7.67M |
|
|
ELEV
118
DELISTED
Elevation Oncology
ELEV
| – | – |
-941,275
| Closed | -$530K |
|
|
ITCI
119
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-163,000
| Closed | -$13.6M |
|
120
Mineralys Therapeutics
MLYS
$1.94B
| – | – |
-1,611,637
| Closed | -$19.8M |
|
|
121
Biogen
BIIB
$20.8B
| – | – |
-509,100
| Closed | -$77.9M |
|